1. Home
  2. EDBL vs ENVB Comparison

EDBL vs ENVB Comparison

Compare EDBL & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Edible Garden AG Incorporated

EDBL

Edible Garden AG Incorporated

HOLD

Current Price

$3.37

Market Cap

3.6M

ML Signal

HOLD

Logo Enveric Biosciences Inc.

ENVB

Enveric Biosciences Inc.

HOLD

Current Price

$2.22

Market Cap

3.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EDBL
ENVB
Founded
2020
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Farming/Seeds/Milling
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.6M
3.0M
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
EDBL
ENVB
Price
$3.37
$2.22
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$120.00
AVG Volume (30 Days)
229.5K
232.9K
Earning Date
01-01-0001
02-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$39,914,675.00
Revenue This Year
$29.56
N/A
Revenue Next Year
$20.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.15
$0.56
52 Week High
$7.54
$13.25

Technical Indicators

Market Signals
Indicator
EDBL
ENVB
Relative Strength Index (RSI) 70.20 32.90
Support Level $3.25 $1.98
Resistance Level $3.98 $2.47
Average True Range (ATR) 0.64 0.23
MACD 0.04 0.02
Stochastic Oscillator 43.66 13.91

Price Performance

Historical Comparison
EDBL
ENVB

About EDBL Edible Garden AG Incorporated

Edible Garden AG Inc is a next-generation controlled environment agriculture farming company. It uses traditional agricultural growing techniques together with technology to grow fresh, organic food, sustainably and safely while improving traceability. The company uses the controlled environment of traditional greenhouse structures, such as glass greenhouses together with hydroponic and vertical greenhouses to sustainably grow organic herbs and lettuces.

About ENVB Enveric Biosciences Inc.

Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.

Share on Social Networks: